iTeos’ pipeline addresses key unmet needs in immuno-oncology by targeting two key PD-1 resistance mechanisms – the Adenosine pathway and Treg suppression. These programs include:
- EOS-850, an Adenosine A2A receptor-specific antagonist which is best-in-class and in early phase clinical trials
- EOS-448, an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody, which is in a Phase 1 clinical trial
iTeos focuses on selected key mechanisms by which the immune system is suppressed in the tumor microenvironment: adenosine pathway and regulatory T cells (Tregs). The identification of specific targets in these pathways are based on immuno-metabolism characterization in tumor micro-environment, gene expression profiles of immune cell subsets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of preclinical models.
iTeos continues to work on target discovery to fuel its expanding portfolio of therapeutic programs in immuno-oncology. iTeos has developed an innovative in vitro phenotyping screening assay that mimics the tumor microenvironment. This target identification platform is used to identify novel targets and rational combinations with standard of cares and our current programs. Collaborations to allow access to patient tumors and to profile the immune cells within will allow us to provide the relevant disease context for our current and future targets.
|Program||Trial Design||Indications||Preclinical||Phase 1||Phase 1b/2a|
|A2A Receptor Antagonist|
|Dose finding, PK/PD||Solid tumors|
|+Pac-Carbo||TNBC||New Mechanism Inhibitor|
|Anti-TIGIT mAb ADCC-enabled|
|Dose Finding, PK/PD||Solid tumors||Anti-CCR8 mAb ADCC-enabled|